Your search for ‘Smart & Biggar’ returned 2,497 results

As we previously reported, Canada will be significantly changing its trademark law.

On April 28, 2017, the Federal Court released a Notice to the Parties and the Profession: Trial Management Guidelines.

As previously reported, the 2018 Federal Budget announced the creation of an Advisory Council on the Implementation of National Pharmacare.

For complete details about these proceedings, click here.

Following release of a white paper in March, on December 9, 2017, Health Canada released proposed amendments to the Food and Drug Regulations under which "clinical summaries, reports...

We provided an update on biosimilars: Health Canada's guidance, approvals and reviews of biosimilars to date, the effect of CETA amendments to biologics, pending patent litigation...

In view of the ongoing COVID-19 pandemic, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed...

INVEGA SUSTENNA (paliperidone palmitate): Janssen v Pharmascience.

As previously reported, the Federal Court of Appeal overturned the Federal Court's conclusion that Apotex failed to mitigate the loss it incurred as a result of Health Canada's tortious conduct...

The Competition Bureau has made it clear that an enforcement priority is the practice of "drip pricing"; that is the advertisement of a price that is unattainable...

The Canadian Agency for Drugs and Technologies in Health (CADTH) announced on March 8, 2018 that, effective April 2, 2018, its Common Drug Review (CDR) ...

As previously reported, Health Canada announced January 1, 2018 as the proposed date for mandatory filing of specified regulatory activity.

On March 19, 2019, Health Canada published a Notice, announcing the launch of its e-Learning tool: Understanding How Medical Devices are Regulated in Canada – Premarket Regulation.

On February 19, 2019, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the 2017 edition of Meds Entry Watch.

As previously reported, British Columbia, Alberta, and New Brunswick have all launched biosimilar initiatives which require that patients switch from certain reference biologics to biosimilars for certain indications.

Canada and the European Union have established distinct frameworks for extending patent protection beyond standard terms to compensate innovators for regulatory approval delays.

The European Medicines Agency continues to be a leader in developing guidance to industry on biosimilar approvals.

On May 8, 2019, Justice Roy dismissed Servier's application for a prohibition order under the pre-amended Patented Medicines (Notice of Compliance) Regulations for Canadian Patent No